MapLight Therapeutics

News

MapLight Therapeutics has made its debut on the Nasdaq, raising $251m for a lead drug that could be a rival to BMS' new schizophrenia drug Cobenfy.

News

Pharvaris has reported positive data from a phase 3 trial of its drug for preventing HAE attacks, setting up marketing applications next year.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.